Download the JEE Main 2025 Physics syllabus PDF from jeemain.nta.nic.in. Get the complete syllabus for JEE Mains 2025, ...
Pfizer’s sasanlimab in combo with BCG improves EFS in patients with BCG-naïve, high-risk non-muscle invasive bladder cancer: New York Monday, January 13, 2025, 13:00 Hrs [IST] ...
Pfizer Inc. (NYSE: PFE) today announced positive topline results from its pivotal Phase 3 CREST trial evaluating sasanlimab, an investigational ...
Pfizer Inc. (NYSE:PFE) released topline results from its Phase 3 CREST trial evaluating sasanlimab, an investigational ...
H.C. Wainwright analyst Andres Maldonado keeps a Buy rating on CG Oncology (CGON) with a $75 price target after Pfizer (PFE) announced positive ...
If approved, Pfizer’s sasanlimab will distinguish itself from Merck’s blockbuster Keytruda as the first PD-1 inhibitor ...
Pfizer on Friday said the pivotal Phase 3 study evaluating sasanlimab in combination with standard-of-care Bacillus Calmette-Guerin, or BCG, as induction therapy with or without maintenance in ...
Pfizer (PFE) announced positive topline results from its pivotal Phase 3 CREST trial evaluating sasanlimab, an investigational anti-PD-1 ...
Pfizer’s Sasanlimab in Combination with BCG Improves Event-Free Survival in Patients with BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer ...
Researchers have published a prospective, randomized and controlled study on the use of extracorporeal photopheresis (ECP) in lung transplantation. The findings could significantly change the standard ...
Tuspetinib based TUS+VEN+AZA triplet therapy is being advanced in the TUSCANY Phase 1/2 trial with the goal of creating an improved frontline therapy for newly diagnosed AML patients that is active ...
Researchers from the Vienna Lung Transplant Program of MedUni Vienna and University Hospital Vienna have published the first ...